Mohammadamin Tavakoli, Ryan J Miller, Mirana Claire Angel, Michael A Pfeiffer, Eugene S Gutman, Aaron D Mood, David Van Vranken, Pierre Baldi
PMechDB: A Public Database of Elementary Polar Reaction Steps
Journal of chemical information and modeling
disease extent ulcerative colitis uc prognostic implications disease course unclear whether efficacy medical therapies moderate severely active uc vary according disease extent enrollment analyzed patient level data 11 phase 2 3 clinical trials advanced therapies patients moderatetosevere uc assess modifications advanced therapy effects disease extent primary outcome clinical response secondary outcomes clinical remission endoscopic responseremission endoscopic improvement mayo clinic subscore induction maintenance studies binary continuous outcomes analyzed using modified poisson regression model mixedeffects model respectively adjusting age sex disease duration concomitant steroid use prior antitnf use effect modifications binary outcomes quantified ratios risk ratio leftsided extensive colitis effect modifications mayo subscores quantified differences differences mean scores leftsided extensive colitis results presented point estimates 95 confidence intervals well pvalues eleven clinical trials enrolling 5450 uc patients infliximab 2 adalimumab 2 golimumab 2 vedolizumab 2 tofacitinib 3 included induction trials evidence suggest effect modification disease extent clinical response tofacitinib ratio rrs 067 95 ci 045 099 p 0049 clinical remission infliximab ratio rrs 033 95 ci 013 085 p 0020 favoring patients extensive colitis evidence suggest effect modification endoscopic improvement clinical outcomes evidence suggest effect modification disease extent clinical remission tofacitinib ratio rrs 044 95 ci 022 089 p 0020 favoring patients extensive colitis symptom subscores mayo clinic score tofacitinib associated greater reduction stool frequency difference differences 037 95 ci 008 065 p 0012 rectal bleeding scores difference differences 025 95 ci 003 047 p 0026 patients extensive colitis compared left sided findings underscore possibility differential efficacy medical therapies according disease distribution results warrant exploration forthcoming trials better inform treatment strategies consideration disease distribution baseline stratification factor clinical trials study receive financial support